Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey.
autoimmune hepatitis
cholestatic liver disease
physician-patient relationship
quality of life
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
13
09
2022
received:
22
06
2022
accepted:
19
09
2022
pubmed:
1
10
2022
medline:
25
1
2023
entrez:
30
9
2022
Statut:
ppublish
Résumé
Autoimmune liver diseases (AILDs) are associated with impaired health-related quality of life (HrQoL). The aim of this project was to identify potentially modifiable factors related to HrQoL in a large transnational cohort of patients with AILDs. A cross-sectional online survey was conducted on patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) or primary sclerosing cholangitis from 15 European countries. HrQoL was measured with EQ-5D-5L and EQ visual analogue scale (EQ-VAS) and analysed in relation to demographic, psychosocial, disease- and treatment-related factors. A Patient Health Questionnaire-2 score >3 indicated relevant depression. Multivariable linear regression analyses were used to identify potentially modifiable factors associated with HrQoL and confidence in treatment whilst adjusting for known confounders. A group of 1178 European patients (79% female, mean age 48 ± 14 years) participated in the study. HrQoL was impaired in all three diseases (mean EQ-5D-5L = 0.75, mean EQ VAS = 68.9), most markedly in PBC (mean EQ-5D-5L = 0.73, mean EQ-VAS = 66.2). Relevant depression, which was detected in 17% of patients, was prominently associated with impaired HrQoL. In the regression analysis, treatment confidence was identified as an important modifiable factor positively contributing to HrQoL. This influence was observable even after adjusting for other covariates including depression. Management in a transplant centre, treatment with azathioprine in AIH, and with ursodeoxycholic acid in PBC, was associated with increased treatment confidence. Finally, improved patient-physician relationships contributed to treatment confidence. Treatment confidence is a relevant modifiable determinant of HrQoL and should be further investigated to improve the standards of care for patients with AILDs.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Autoimmune liver diseases (AILDs) are associated with impaired health-related quality of life (HrQoL). The aim of this project was to identify potentially modifiable factors related to HrQoL in a large transnational cohort of patients with AILDs.
METHODS
METHODS
A cross-sectional online survey was conducted on patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) or primary sclerosing cholangitis from 15 European countries. HrQoL was measured with EQ-5D-5L and EQ visual analogue scale (EQ-VAS) and analysed in relation to demographic, psychosocial, disease- and treatment-related factors. A Patient Health Questionnaire-2 score >3 indicated relevant depression. Multivariable linear regression analyses were used to identify potentially modifiable factors associated with HrQoL and confidence in treatment whilst adjusting for known confounders.
RESULTS
RESULTS
A group of 1178 European patients (79% female, mean age 48 ± 14 years) participated in the study. HrQoL was impaired in all three diseases (mean EQ-5D-5L = 0.75, mean EQ VAS = 68.9), most markedly in PBC (mean EQ-5D-5L = 0.73, mean EQ-VAS = 66.2). Relevant depression, which was detected in 17% of patients, was prominently associated with impaired HrQoL. In the regression analysis, treatment confidence was identified as an important modifiable factor positively contributing to HrQoL. This influence was observable even after adjusting for other covariates including depression. Management in a transplant centre, treatment with azathioprine in AIH, and with ursodeoxycholic acid in PBC, was associated with increased treatment confidence. Finally, improved patient-physician relationships contributed to treatment confidence.
CONCLUSION
CONCLUSIONS
Treatment confidence is a relevant modifiable determinant of HrQoL and should be further investigated to improve the standards of care for patients with AILDs.
Identifiants
pubmed: 36177700
doi: 10.1111/liv.15440
pmc: PMC10091761
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-392Subventions
Organisme : Consumers, Health, Agriculture and Food Executive Agency
ID : 869229
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Hepatol. 2012 Dec;57(6):1299-304
pubmed: 22871503
J Hepatol. 2022 Sep;77(3):761-806
pubmed: 35738507
Mayo Clin Proc. 2006 Oct;81(10):1361-7
pubmed: 17036562
Hepatology. 2013 Jul;58(1):273-83
pubmed: 23471852
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91
pubmed: 11124735
World J Hepatol. 2021 Nov 27;13(11):1642-1652
pubmed: 34904034
PLoS One. 2020 Jul 6;15(7):e0234624
pubmed: 32628685
BMJ Open. 2013 May 28;3(5):
pubmed: 23793686
J Hepatol. 2014 Mar;60(3):618-24
pubmed: 24240053
JAMA. 2020 Jun 9;323(22):2290-2300
pubmed: 32515813
Clin Epidemiol. 2020 Feb 05;12:143-151
pubmed: 32104098
PLoS One. 2020 Sep 11;15(9):e0239035
pubmed: 32915906
Arch Intern Med. 2000 Aug 14-28;160(15):2257-60
pubmed: 10927721
Metab Brain Dis. 2004 Dec;19(3-4):421-9
pubmed: 15554432
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
J Hepatol. 2018 Mar;68(3):577-585
pubmed: 29113911
Liver Int. 2015 Jun;35(6):1764-71
pubmed: 25388280
Hepatol Commun. 2020 Jan 16;4(3):399-408
pubmed: 32140656
Med Care. 1998 Feb;36(2):180-9
pubmed: 9475472
Hepatology. 2019 Dec;70(6):2232-2233
pubmed: 30773711
BMJ Open. 2019 Dec 29;9(12):e033353
pubmed: 31888936
Liver Int. 2019 Jan;39(1):215-221
pubmed: 30204306
Orphanet J Rare Dis. 2019 Jul 8;14(1):169
pubmed: 31287000
J Hepatol. 2009 Aug;51(2):237-67
pubmed: 19501929
Am J Geriatr Psychiatry. 2014 Oct;22(10):1029-38
pubmed: 23768681
Liver Int. 2023 Feb;43(2):381-392
pubmed: 36177700
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
JAMA Intern Med. 2014 Mar;174(3):399-407
pubmed: 24276929
Hepatology. 2018 Oct;68(4):1487-1497
pubmed: 29663477
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1216-23
pubmed: 25209683
Liver Int. 2015 Sep;35(9):2194-201
pubmed: 25546575
J Fam Pract. 1998 Sep;47(3):213-20
pubmed: 9752374
J Affect Disord. 2010 Apr;122(1-2):86-95
pubmed: 19616305
Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):52-8
pubmed: 25132012
Milbank Q. 2001;79(4):613-39, v
pubmed: 11789119
Milbank Q. 1996;74(2):171-89
pubmed: 8632733
Psychol Rep. 1990 Dec;67(3 Pt 2):1091-100
pubmed: 2084735
J Clin Oncol. 1999 Jan;17(1):371-9
pubmed: 10458256